Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer.
BackgroundLiquid biopsies enable the detection of circulating tumor DNA (ctDNA).However, the clinical significance Wraps of KRAS-mutated ctDNA for pancreatic cancer has been inconsistent with respect to its prognostic and predictive potential.Methods and findingsA total of 422 blood samples were collected from 78 patients undergoing treatments for